These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 14987911)
1. A systematic review of economic analyses of low-molecular-weight heparin for the treatment of venous thromboembolism. Sprague S; Cook DJ; Anderson D; O'Brien BJ Thromb Res; 2003; 112(4):193-201. PubMed ID: 14987911 [TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Gould MK; Dembitzer AD; Sanders GD; Garber AM Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368 [TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Raskob GE Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157 [TBL] [Abstract][Full Text] [Related]
5. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295 [TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy. Reeves P; Cooke J; Lloyd A; Hutchings A Pharm World Sci; 2004 Jun; 26(3):160-8. PubMed ID: 15230364 [TBL] [Abstract][Full Text] [Related]
7. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. Huse DM; Cummins G; Taylor DC; Russell MW Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346 [TBL] [Abstract][Full Text] [Related]
9. Current and potential uses of low molecular weight heparin: a review and an economic analysis. Seo P; Locke CF Am J Manag Care; 2000 Apr; 6(4):498-506; quiz 507-8. PubMed ID: 10977456 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin. Jones TE; Smith BJ; Polasek JF Expert Opin Pharmacother; 2004 Sep; 5(9):1887-97. PubMed ID: 15330727 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism. Bernardi E; Prandoni P Curr Opin Pulm Med; 2005 Sep; 11(5):363-7. PubMed ID: 16093806 [TBL] [Abstract][Full Text] [Related]
12. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring. Hull RD; Pineo GF; Stein P Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652 [TBL] [Abstract][Full Text] [Related]
13. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ Value Health; 2005; 8(3):191-200. PubMed ID: 15877591 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. Schousboe JT; Brown GA J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173 [TBL] [Abstract][Full Text] [Related]
15. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Hull RD; Pineo GF; Raskob GE Haemostasis; 1998; 28 Suppl 3():8-16. PubMed ID: 10069757 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ; JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Aujesky D; Smith KJ; Cornuz J; Roberts MS Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815 [TBL] [Abstract][Full Text] [Related]
18. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal. Heaton D; Pearce M Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614 [TBL] [Abstract][Full Text] [Related]
19. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Segal JB; Bolger DT; Jenckes MW; Krishnan JA; Streiff MB; Eng J; Tamariz LJ; Bass EB Am J Med; 2003 Sep; 115(4):298-308. PubMed ID: 12967695 [TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. Anderson DR; O'Brien BJ Pharmacoeconomics; 1997 Jul; 12(1):17-29. PubMed ID: 10169385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]